Thursday, November 10, 2022 9:54:50 PM
Also Known As
John Rodney Varner, Rodney R Varner, Rodney Te Varner, Rodney A Varner, Jrodney Rodney Varner, Rodney Varner Ave
Imagine you could go through life with this many alias?
Genprex firing of Michael T Redman is not enough?
John Rodney Varner has so far produce nothing but dilution buying and selling shares of Genprex Inc?
Or Rodney Varner? Whatever the hell he calls himself today?
Then pays himself almost a million a year to do so?
Is it a scam money laundering felony to obtain a shell with the sole purpose of dilution shares and paying yourself?
How else is Rodney John Varner John Varner Rodney paying himself?
Profit?
Is none?
Jail time has to be the only outcome if John aka Rodney aka JVarner is involved in faking studies to sell shares?
And judging by the raising O/S and his pay so far that's about all he is producing?
Am I wrong Johnathan? Johnny?
IMO
John Rodney Varner, Rodney R Varner, Rodney Te Varner, Rodney A Varner, Jrodney Rodney Varner, Rodney Varner Ave
Imagine you could go through life with this many alias?
Genprex firing of Michael T Redman is not enough?
John Rodney Varner has so far produce nothing but dilution buying and selling shares of Genprex Inc?
Or Rodney Varner? Whatever the hell he calls himself today?
Then pays himself almost a million a year to do so?
Is it a scam money laundering felony to obtain a shell with the sole purpose of dilution shares and paying yourself?
How else is Rodney John Varner John Varner Rodney paying himself?
Profit?
Is none?
Jail time has to be the only outcome if John aka Rodney aka JVarner is involved in faking studies to sell shares?
And judging by the raising O/S and his pay so far that's about all he is producing?
Am I wrong Johnathan? Johnny?
IMO
Everything I post, is In my own opinion, I don't care what you think about it, if you disagree, post it like I do. If you buy or sell stock based on what I say, your a lunatic and should not be trading. Have a great day!
Recent GNPX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:05:14 PM
- Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting • PR Newswire (US) • 05/14/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:35:46 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/11/2026 09:52:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 12:00:55 PM
- Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer • PR Newswire (US) • 04/30/2026 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 08:47:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 11:07:21 AM
- Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting • PR Newswire (US) • 04/28/2026 11:00:00 AM
- Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting • PR Newswire (US) • 04/22/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 11:02:55 AM
- Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy • PR Newswire (US) • 04/21/2026 11:00:00 AM
- Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting • PR Newswire (US) • 04/20/2026 11:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 08:34:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:34:58 PM
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting • PR Newswire (US) • 03/18/2026 11:00:00 AM
- Genprex to Participate at BIO Europe Spring 2026 • PR Newswire (US) • 03/10/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 11:33:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 01:08:16 PM
- Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer • PR Newswire (US) • 02/23/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/10/2026 01:04:05 PM
- Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers • PR Newswire (US) • 02/10/2026 01:00:00 PM
